Stifel Raises Thermo Fisher Scientific (TMO) Price Target to $775

Stifel reiterated its Buy rating on Thermo Fisher Scientific Inc. [TMO] on October 22, 2026, while lifting its price target to $775.00 from $650.00. The research note outlines a bullish forward-looking stance on the healthcare equipment and diagnostics provider as shares continue trading near historical ranges.

TMO Thermo Fisher Scientific Inc.

$694.02 ▲ +17.46% year to date

1M 3M YTD

Daily close · Oct 21, 2026

Stifel's Call on Thermo Fisher Scientific

In its October 22, 2026 note, Stifel kept its Buy rating on the company and moved its price target up from $650.00 to $775.00. The firm joins a broader chorus of Wall Street analysts adjusting their views on the company following recent market developments.

Other Institutional Activity in Thermo Fisher Scientific

Franklin Resources, Inc. grew its holdings by 458,515 shares, ending with 7,271,514 shares worth about $4,932,158,678.00 in its quarter ended June 30, 2026, marking a 6.7% increase.

Thermo Fisher Scientific Inc. Stock Up 1.0%

Thermo Fisher Scientific closed at $678.43 on October 22, 2026. The stock recently traded around $694.02 as of October 22, 2026, sitting up about 2.3% since that event close. The shares rest well above their 50-day moving average of $641.93 and comfortably ahead of their 200-day moving average of $548.71, while trading below their 52-week high of $705.79.

Recent Earnings

Thermo Fisher Scientific reported $47,351,001,088.00 in trailing-twelve-month revenue alongside an earnings per share of $18.96. The next earnings release is slated for January 28, 2027.

Dividend

Thermo Fisher Scientific pays an annual dividend rate of $1.88 per share, giving investors a 0.27% dividend yield backed by a 9.7% payout ratio.

Insider Buying and Selling at Thermo Fisher Scientific Inc.

Company insiders executed several transactions prior to the analyst update. On August 19, 2026, officer Lisa P Britt sold 11,440 shares at $613.12 for $7,014,093.00. Chief Executive Officer Marc N Casper sold 20,000 shares on August 21, 2026, valued at $12,561,823.00, followed by another sale of 275 shares on August 24, 2026, worth $172,439.00. Later, President Gianluca Pettiti sold 4,133 shares at $614.38 on August 31, 2026, totaling $2,539,233.00.

Analysts Set New Price Targets

Several other firms updated their outlooks on October 22, 2026. Barclays maintained its Overweight rating while raising its target to $775.00 from $750.00. RBC Capital maintained a Sector Perform rating and moved its target to $730.00 from $580.00. TD Cowen kept a Buy rating and increased its target to $810.00 from $760.00. Baird maintained an Outperform rating and adjusted its target to $756.00 from $723.00. Across the broader analyst community, the consensus stands at a strong buy with a mean price target of $706.69 derived from 26 opinions.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. operates in the healthcare space, providing life sciences solutions, analytical tools, diagnostic products, and laboratory services around the globe. Headquartered in Waltham, Massachusetts, the firm employs 125,000 people and serves research, biotech, and pharmaceutical clients.

Bottom Line

Investors will look toward the company's next earnings report on January 28, 2027, for further insight into financial performance. Market participants continue tracking institutional flows and shifting price targets across the healthcare sector.